GATC Health Takes the Stage at the DIA Global Annual Meeting—Life Sciences’ Largest Event
June 24, 2026 — Last week at the DIA Global Annual Meeting in Philadelphia, GATC Health President Dr. Rahul Gupta joined an esteemed group of industry experts for the kickoff plenary panel, “Hidden Potential: Turning Today’s Science into Tomorrow’s Cures.”
The panel featured an exceptional lineup of experts (from L-R):
- Lawrence Tallon – Chief Executive Officer, MHRA
- Greg Sarafin – Chief Administrative Officer, Sovereign AI
- Dave Pfeiffer – Senior Vice President, Head of ARCAS, Acrisure Re Bio-Tech
- Dr. Rahul Gupta – President, GATC Health
- Moderator: Audrey Greenberg – Venture Partner & Chair, Mayo Venture Partners
Dr. Gupta’s participation alongside other global thought leaders underscores how GATC Health’s Operon® Platform is being used to accelerate breakthroughs in drug development and shape the future of financing in the industry.
The GATC Health team was on the ground for the remainder of the week, taking meetings and engaging attendees at our booth.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
BioAtla Partners with GATC Health to Utilize Disruptive AI to Advance Phase 3 Cancer Treatment and Co-Develop Longevity Therapeutic
January 8, 2026—GATC Health and BioAtla (Nasdaq: BCAB) have partnered to advance late-stage development of a promising cancer drug, Oz-V, a…
Read more
GATC Health Strengthens Commercial and Pharma Strategy Leadership to Accelerate Market Adoption of Its AI Platform
IRVINE, CA — Feb. 26, 2026 — GATC Health, a leading tech-bio company leveraging AI to transform drug discovery and development, is pro…
Read moreGATC Health Takes the Main Stage at Fierce Biotech Week
May 19, 2026 — GATC Health is pleased to share that Dr. Rahul Gupta, President of GATC Health, was featured at Fierce Biotech Week as a pa…
Read more